China has included Changchun High-Tech Industry's (SHE:000661) two drugs in the country's national basic medical insurance catalog, according to a Tuesday filing with the Shenzhen bourse.
Authorities approved for inclusion in the insurance program a growth hormone injection to treat endogenous growth hormone deficiency, growth disorders in girls due to Turner's hypogonadism, and for idiopathic short stature, the filing said.
The other drug is for anorexia in AIDS and cancer patients, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments